Antitrust Lawsuit | Case Settlements | Medical Industry

Introduction: Medical Device Antitrust Decision

In a significant decision with wide implications for the medical device industry, a federal jury has awarded Innovative Health, LLC $147 million in damages after finding that Biosense Webster, Inc., a subsidiary of Johnson & Johnson, violated U.S. antitrust laws by engaging in exclusionary and anti-competitive conduct.

The verdict, delivered in the U.S. District Court for the Central District of California, concludes a high-stakes trial over alleged efforts by Biosense Webster to maintain a monopoly in the market for cardiac mapping and ablation catheters — devices commonly used in treating heart arrhythmias such as atrial fibrillation.

The Allegations: Monopoly Maintenance and Market Exclusion

Innovative Health, a medical device reprocessor, accused Biosense Webster of unlawfully attempting to block hospitals and providers from using reprocessed electrophysiology (EP) catheters — a lower-cost alternative to brand-new, single-use devices.

Specifically, the plaintiff alleged that Biosense Webster:

• Threatened hospitals and doctors with reduced support or service if they used reprocessed catheters;
• Bundled its products in a way that penalized customers for choosing reprocessed options;
• Imposed restrictive contracts and pricing structures designed to exclude competitors from the market;
• Acted to protect its monopoly in violation of Section 2 of the Sherman Act.

According to the complaint, these actions created artificial barriers for reprocessors and forced hospitals to continue purchasing high-cost, disposable devices rather than opting for FDA-cleared, reprocessed equivalents.

The Verdict and Damages

After a multi-week trial, the jury unanimously found that Biosense Webster had willfully maintained its monopoly in the EP catheter market through anticompetitive conduct, and awarded $147 million in damages to Innovative Health. The jury rejected the defense’s arguments that its practices were lawful efforts to ensure patient safety and product quality.

Although the damages awarded were compensatory, treble damages could be imposed under federal antitrust law, potentially increasing Biosense Webster’s financial liability to over $400 million, pending post-trial motions and appeals.

Legal Significance

This case marks one of the most substantial antitrust verdicts in recent memory involving the medical device industry, and it underscores the legal risks associated with aggressive business tactics in markets for FDA-regulated technologies.

“This is a clear message that dominant firms in the medical device space cannot use market power to suppress legitimate, FDA-cleared alternatives,” said antitrust attorney Rachel Donovan, who was not involved in the case. “The jury saw this as a classic case of exclusionary conduct under Sherman Act §2.”

The verdict also affirms the legality and viability of medical device reprocessing as a competitive force — an increasingly important factor in hospital cost-containment and environmental sustainability.

Biosense Webster’s Response and Next Steps

Biosense Webster has indicated that it disagrees with the verdict and plans to challenge the decision.

“We respectfully disagree with the jury’s findings and are reviewing our legal options,” the company said in a statement. “Patient safety and product integrity have always been our highest priorities.”

Legal experts anticipate motions for judgment as a matter of law (JMOL) or a new trial, and possibly an appeal to the Ninth Circuit.

Broader Industry Impacts

This decision could have ripple effects across several domains:

• Medical Device Makers: Firms with large market shares may reassess bundling, exclusivity, and pricing practices that could raise antitrust concerns.
• Reprocessors: Companies offering reprocessed devices now have stronger legal precedent to challenge exclusionary tactics by original manufacturers.
• Hospitals and Group Purchasing Organizations (GPOs): May feel more confident in selecting cost-effective, reprocessed alternatives without fear of manufacturer retaliation.

Notably, the ruling aligns with growing federal scrutiny of anticompetitive behavior in healthcare, including in the areas of pharmaceuticals, PBMs, and medical devices.

Conclusion

The $147 million verdict in Innovative Health v. Biosense Webster stands as a milestone in antitrust enforcement in the medical technology sector. As the case potentially moves into post-trial litigation and appeal, it serves as a powerful reminder that even well-established companies face significant exposure when their market strategies cross into exclusionary territory.

For legal departments, compliance teams, and regulatory counsel in the medtech industry, this case is a must-watch.